SCHEMBL16405366

SCHEMBL16405366

CCCC(NC(C)=O)C(=O)SCC(NC(C)=O)C(=O)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PAM P19021 1/20 0.34
▸ SIRT6 Q8N6T7 1/20 0.33
▸ SIRT1 Q96EB6 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ THPO P40225 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ CTSS P25774 1/20 0.31
▸ CTSK P43235 1/20 0.31
▸ PSEN1 P49768 1/20 0.30
▸ PSEN2 P49810 1/20 0.30
▸ APH1B Q8WW43 1/20 0.30
▸ NCSTN Q92542 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16405365 0.87 KDM4E (0.38) PAMKDM4EMAPTTHRBALOX15
SCHEMBL13142864 0.84 PAM (0.35) PAMKDM4EMAPTTHRBALOX15
SCHEMBL12229210 0.84 KDM4E (0.39) SIRT6SIRT1KDM4EMAPTTHRB
SCHEMBL13142865 0.83 KDM4E (0.47) PAMKDM4EMAPTTHRBALOX15
SCHEMBL13142863 0.80 MAPT (0.37) PAMKDM4EMAPTTHRBALOX15
SCHEMBL23143030 0.77 MAPT (0.39) PAMKDM4EMAPTTHRBALOX15
SCHEMBL23142965 0.76 MAPT (0.36) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL13179881 0.75 PAM (0.33) PAMKDM4EMAPTTHRBALOX15
SCHEMBL26754226 0.74 MAPT (0.37) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL24850734 0.73 KDM4E (0.42) SIRT6SIRT1KDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150025006-A1 Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2015-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025006-A1 Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders IAPP, AMY2A, GPR119 PAM 1015/4885SIRT6 991/4885SIRT1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback